![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.135 | -2.91% | 4.51 | 4.41 | 4.99 | 4.53 | 4.51 | 4.53 | 150,843 | 11:53:49 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.51 | 9.35M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/7/2020 11:24 | Simplistically,you could make analogies between this treatment and the use of RetrovirAZT for the AIDs virus. | ![]() steeplejack | |
20/7/2020 11:21 | many people now will not want a vaccine is the answer feekl for people who sold to early this morning so often see this at shares early sellers missing out on bigger rises while have sold some myself to move money back to ncyt with the £5 billion governmen contract to be announced thinking if ncyt win some of it how good a rise might be seen there | ![]() bunz3 | |
20/7/2020 11:04 | O/t check NSF, about to explode as seller is done imo and hsbc took a good chunk there. As always dyor | ![]() jungmana | |
20/7/2020 10:59 | Synairgen's SNG001 shows strong promise in COVID-19 trial | ![]() sikhthetech | |
20/7/2020 10:55 | Home kits. Massive. Forget the vaccines nobody wants the dodgy baggage associated with Gates involvement. | tidy 2 | |
20/7/2020 10:49 | Valuation off the clock for Cv19 alone for Sng. U.K. Companyâs Drug Cuts Covid-19 RiskShares of Synairgen Plc, a tiny pharmaceutical firm born out of a U.K. university, soared after the company said its experimental drug cut the risk of developing the worst symptoms of Covid-19.âValuing the Covid-19 opportunity is nigh on impossible,â? FinnCap analyst Mark Brewer said in a note to clients, adding that upcoming discussions with regulators should clarify SNG001âs route to market. Finncap is also corporate broker to the company.Synairgen, founded by three professors from the University of Southampton, previously partnered with AstraZeneca -Bloomberg | tidy 2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions